Mesoblast raising AU$97M for registration trials in GVHD, chronic back pain
Regenerative medicine company Mesoblast Ltd. plans to raise AU$97 million (US$64.5 million) to conduct additional phase III registration trials for its allogeneic stem cell treatment for steroid-refractory acute graft-vs.-host disease and for chronic back pain, as required by the U.S. FDA.
Mesoblast Ltd Mesoblast Ltd Acute Graft Vs Host Disease Remestemcel L Allogeneic Stem Cell Treatment Steroid Refractory Acute Graft Vs Host Disease
Source: bioworld.com